Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results encourage the development of DYRK1A inhibitors as drug candidates to treat cognitive deficits associated with DS and AD.
|
30115750 |
2018 |
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of DYRK1A attenuates cognitive dysfunctions in animal models for both DS and Alzheimer's disease (AD).
|
29985601 |
2018 |
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome.
|
30332747 |
2018 |
Impaired cognition
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
|
28377597 |
2017 |
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that chronic Dyrk1 inhibition reversed cognitive deficits in 3xTg-AD mice.
|
28779511 |
2017 |
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
DYRK1A hyperactivity appears to contribute to the development of a number of human malignancies and to cognitive deficits observed in Down syndrome and Alzheimer's disease.
|
28766366 |
2017 |
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Various mouse models and studies from human brains have implicated an HSA21 gene, the serine/threonine kinase DYRK1A, as a candidate for inducing cognitive dysfunction.
|
24801365 |
2014 |
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
MNB/DYRK1A (Minibrain/dual specificity tyrosine phosphorylation-regulated kinase 1A) has possibly been the most extensively studied chromosome 21 gene during the last decade due to the remarkable correlation of its functions in the brain with important DS neuropathologies, such as neuronal deficits, dendrite atrophy, spine dysgenesis, precocious Alzheimer's-like neurodegeneration, and cognitive deficits.
|
24152332 |
2014 |
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
The DYRK1A gene is located within the Down syndrome critical region (DSCR) on human chromosome 21 and current research suggests that overexpression of DYRK1A may be a significant factor leading to cognitive deficits in people with Alzheimer's disease (AD) and Down syndrome (DS).
|
23173067 |
2012 |
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our results suggest that aberrant Dyrk1A-mediated phosphorylation of the endocytic machinery perturbs synaptic vesicle endocytosis, which may contribute to synaptic dysfunctions and cognitive deficits associated with DS.
|
21135538 |
2010 |
Impaired cognition
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genetic-dissection studies carried out with Down syndrome (DS) murine models point to the critical contribution of Dyrk1A overexpression to the motor abnormalities and cognitive deficits displayed in DS individuals.
|
18940310 |
2008 |
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among those genes is DYRK1A encoding dual-specificity proline-directed serine/treonine kinase, which, as documented by animal studies, can potentially contribute to cognitive deficits in DS.
|
17145134 |
2007 |
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review we compile and discuss experimental evidences, which support the involvement of MNB/DYRK1A in several neuropathologies and cognitive deficits of Down syndrome.
|
15068245 |
2003 |
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.
|
11555628 |
2001 |